Kidney disease and the metabolic syndrome

American Journal of the Medical Sciences

Volumn 330, Issue 6, 2005, Pages 319-325

  Zhang, Rubin ^a   Liao, Jie ^a   Morse, Stephen ^a   Donelon, Shawn ^a   Reisin, Efrain ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

Author keywords

Chronic kidney disease; Insulin resistance; Metabolic syndrome; Obesity; Proteinuria

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; CLOFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; RECEPTOR SUBTYPE; ROSIGLITAZONE; TELMISARTAN; TROGLITAZONE;

ADIPOSE TISSUE; ALBUMINURIA; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET RESTRICTION; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EPIDEMIC; EXERCISE; GLOMERULOSCLEROSIS; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FIBROSIS; METABOLIC SYNDROME X; MICROALBUMINURIA; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOSIS; URINARY EXCRETION; WEIGHT REDUCTION;

EID: 29244476902     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200512000-00010     Document Type: Conference Paper

References (65)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel 3). Final report. Circulation 2002;106:3143-421.
2. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002;287:356-9.
4. Park Y, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1998-1994. Arch Intern Med 2003;163:427-36.
5. Mokad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
6. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. AJKD 2003;41:1-12.
7. Hoehner CM, Greenlund KJ, Rith-Najarian S, et al. Association of the insulin resistance syndrome and microalbuminuria among nondiabetic native Americans. The Inter-Tribal Heart Project. J Am Soc Nephrol 2002;13:1626-34.
8. Chen J, Muntner P, Hamm L, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004;140:167-74.
9. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003;16:952-8.
10. Chen J, Muntner P, Hamm L, et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003;14:469-77.
11. Zhang R, Reisin E. Obesity-hypertension: the effects on cardiovascular and renal systems. J Hypertens 2000;13:1308-14.
12. Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kid Dis 1992;20:629-34.
13. Kambham N, Markowitz GS, Valeri AM, et al. Obesityrelated glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498-509.
14. U.S. Renal Data System. USRDS 2003 15th Annual Data Report: Atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
15. Reisin E, Messerli FG, Ventura HO, et al. Renal hemodynamic studies in obesity hypertension. Hypertension 1995;26:610-5.
16. Hall JE. Mechanism of abnormal renal sodium handing in obesity hypertension. Am J Hypertens. 1997;10:49S-55S.
17. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278:F817-22.
18. Reisin E. Obesity and the kidney connection. Am J Kid Dis 2001;38:1129-34.
19. Cusumano AM, Bodkin NL, Hansen BC, et al. Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging Rhesus monkeys. AJKD 2002;40:1075-85.
20. Bodkin NL, Alexander TM, Ortmeyer HK, et al. Mortality and morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci Med Sci 2003;58:212-9.
21. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12:1211-7.
22. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:H1597-602.
23. Raji A, Seely EW, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-8.
24. Kosegawa I, Katayama S, Kikuchi C, et al. Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. Hypertens Res 1996;19:37-41.
25. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 2004;15:2775-91.
26. Abrass CK, Spicer D, Raugi GJ. Insulin induces a change in extracellular matrix glycoproteins synthesized by rat mesangial cells in culture. Kidney Int 1994;46:613-20.
27. Wolf G, Chen S, Han DC, et al. Leptin and renal disease. Am J Kidney Dis 2002;39:1-11.
28. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-800.
29. Zhang R, Thakur V, Reisin E. Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension. J Human Hypertens 2002;16:819-27.
30. Kamijo A, Kimura K, Sugaya T, et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002;62:1628-37.
31. Unger RH. Minireview: Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-65.
32. Mulyadi L, Stevens C, Munro S, et al. Body fat distribution and total body fat as risk factors for microalbuminuria in the obese. Ann Nutr Metab 2001;45:67-71.
33. Morales E, Vlaero A, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319-27.
34. Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000;58:2111-8.
35. Lackland DT, Bendall HE, Osmond C, et al. Low birth weights contribute to high rates of early-onset chronic renal failure in the southeastern United States. Arch Intern Med 2000;160:1472-6.
36. Osmond C, Barker DJ. Fetal, infant, and childhood growth are predictors of coronary heart disease, diabetes, and hypertension in adult men and women. Environ Health Perspect 2000;108(Suppl 3):545-53.
37. Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al. Microalbuminuria is associated with insulin resistance in non-diabetic subjects: the Insulin Resistance Atherosclerosis study. Diabetes 1998;47:793-800.
38. Castro JP, El-Atat FA, McFarlane SI, et al. Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep 2003;5:393-401.
39. Mangrum A, Bakris GL. Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. J Diabetes Complications 1997;11:352-7.
40. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-8.
41. Yusuf S, Sleight P, Pogue X, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
42. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86.
43. Guan Y. PPAR family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004;15:2801-15.
44. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 2001;60:14-30.
45. Guan Y, Breyer MD. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease. Minerva Urol Nephrol 2002;54:65-79.
46. Park CW, Zhang Y, Fan XF, et al. A PPAR alpha agonist improves diabetic nephropathy in db/db mice. J Am Soc Nephrol 2003;14:393A.
47. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001;59:260-9.
48. Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-32.
49. McCarthy KJ, Routh RE, Shaw W, et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;58:2341-50.
50. Baylis C, Atzpodien EA, Freshour G, et al. Peroxisome proliferator-activated receptor γ agonist provides superior renal protection versus angiotension-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003;307:854-60.
51. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12.
52. Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000;14:250-4.
53. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-7.
54. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-9.
55. Guo B, Koya D, Isono M, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:200-8.
56. Chana RS, Lewington AJ, Brunskill NJ. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cell: thiazolidinediones are partial PPAR gamma agonist. Kidney Int 2004;65:2081-90.
57. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-alpha activity. Circulation 2004;109:2054-7.
58. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin 2 receptor antagonist with selective PPAR-modulating activity. Hypertension 2004;43:993-1002.
59. Hao CM, Redha R, Morrow J, et al. Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem 2002;277:21341-45.
60. Hegarty BD, Furler SM, Oakes ND, et al. PPAR activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo: a study using the novel PPAR (alpha)/(gamma) agonist Tesaglitazar. Endocrinology 2004;145:3158-64.
61. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003;92:35i-42i.
62. Lane MA, Ingram DK, Roth GS. Calorie restriction in nonhuman primates: effects on diabetes and cardiovascular disease risk. Toxicol Sci 1999;52:41-8.
63. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
64. Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish diabetes prevention study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230-6.
65. Praga M, Hernandez E, Andres A, et al. Effects of body weight and capital treatment on proteinuria associated with obesity. Nephron 1995;70:35-41.